User login
Latin American countries have a high rate of SARS-CoV-2 infection and some of the highest COVID-19 deaths worldwide. Brazil, Colombia, Argentina, and Mexico have reported the highest number of confirmed cases. More recently has been reported that in series form US and Europe the mortality of COVID-19 has not been as high as reported in other hematological conditions and the response to vaccination also has bene described as high. In a recent report, Pagnano et al. (Leuk Lymphoma. 2021) has recently reported the clinical evolution and outcome of COVID-19 in patients with chronic myeloid leukemia in Latin America. In an observational multicenter study with a total of 92 patients with COVID-19 between March and December 2020 with 26% of whom were severe or critical. Eighty-one patients recovered (88%), and 11 (11.9%) died from COVID-19. Almost half of them had at least one comorbidity. Patients with a major molecular response presented superior overall survival compared to patients with no major molecular response (91 vs. 61%, respectively; P = 0.004). Patients in treatment-free remission and receiving tyrosine kinase inhibitors showed higher survival rates (100 and 89%) than patients who underwent hematopoietic stem cell transplantation and those who did not receive tyrosine kinase inhibitors (50 and 33%).
Currently the most common reason for TKI discontinuation is intolerance. Ma et al (Leuk Res. 2021) reports the long-term outcomes associated with switch to an alternative TKI after first-line therapy with a 2GTKI. Of 232 patients who initiated a 2GTKI during the study period, 76 (33 %) switched to an alternative TKI. Reasons for switching included intolerance (79 %) and resistance (21 %). Among the 60 patients who switched due to intolerance, 53 (88 %) were able to achieve or maintain a major molecular response (MMR) with 5-year progression-free survival (PFS) 90.5 % (95 % CI 90.4–90.6 %). However, amongst the 16 patients who switched due to resistance, 8 patients (50 %) were able to achieve MMR with 5-year PFS 80.4 % (95 % CI 80.2–80.6 %). Most patients who switched due to intolerance remained on their second-line TKI. Patients who switch for intolerance continue to enjoy excellent long term clinical outcomes.
Latin American countries have a high rate of SARS-CoV-2 infection and some of the highest COVID-19 deaths worldwide. Brazil, Colombia, Argentina, and Mexico have reported the highest number of confirmed cases. More recently has been reported that in series form US and Europe the mortality of COVID-19 has not been as high as reported in other hematological conditions and the response to vaccination also has bene described as high. In a recent report, Pagnano et al. (Leuk Lymphoma. 2021) has recently reported the clinical evolution and outcome of COVID-19 in patients with chronic myeloid leukemia in Latin America. In an observational multicenter study with a total of 92 patients with COVID-19 between March and December 2020 with 26% of whom were severe or critical. Eighty-one patients recovered (88%), and 11 (11.9%) died from COVID-19. Almost half of them had at least one comorbidity. Patients with a major molecular response presented superior overall survival compared to patients with no major molecular response (91 vs. 61%, respectively; P = 0.004). Patients in treatment-free remission and receiving tyrosine kinase inhibitors showed higher survival rates (100 and 89%) than patients who underwent hematopoietic stem cell transplantation and those who did not receive tyrosine kinase inhibitors (50 and 33%).
Currently the most common reason for TKI discontinuation is intolerance. Ma et al (Leuk Res. 2021) reports the long-term outcomes associated with switch to an alternative TKI after first-line therapy with a 2GTKI. Of 232 patients who initiated a 2GTKI during the study period, 76 (33 %) switched to an alternative TKI. Reasons for switching included intolerance (79 %) and resistance (21 %). Among the 60 patients who switched due to intolerance, 53 (88 %) were able to achieve or maintain a major molecular response (MMR) with 5-year progression-free survival (PFS) 90.5 % (95 % CI 90.4–90.6 %). However, amongst the 16 patients who switched due to resistance, 8 patients (50 %) were able to achieve MMR with 5-year PFS 80.4 % (95 % CI 80.2–80.6 %). Most patients who switched due to intolerance remained on their second-line TKI. Patients who switch for intolerance continue to enjoy excellent long term clinical outcomes.
Latin American countries have a high rate of SARS-CoV-2 infection and some of the highest COVID-19 deaths worldwide. Brazil, Colombia, Argentina, and Mexico have reported the highest number of confirmed cases. More recently has been reported that in series form US and Europe the mortality of COVID-19 has not been as high as reported in other hematological conditions and the response to vaccination also has bene described as high. In a recent report, Pagnano et al. (Leuk Lymphoma. 2021) has recently reported the clinical evolution and outcome of COVID-19 in patients with chronic myeloid leukemia in Latin America. In an observational multicenter study with a total of 92 patients with COVID-19 between March and December 2020 with 26% of whom were severe or critical. Eighty-one patients recovered (88%), and 11 (11.9%) died from COVID-19. Almost half of them had at least one comorbidity. Patients with a major molecular response presented superior overall survival compared to patients with no major molecular response (91 vs. 61%, respectively; P = 0.004). Patients in treatment-free remission and receiving tyrosine kinase inhibitors showed higher survival rates (100 and 89%) than patients who underwent hematopoietic stem cell transplantation and those who did not receive tyrosine kinase inhibitors (50 and 33%).
Currently the most common reason for TKI discontinuation is intolerance. Ma et al (Leuk Res. 2021) reports the long-term outcomes associated with switch to an alternative TKI after first-line therapy with a 2GTKI. Of 232 patients who initiated a 2GTKI during the study period, 76 (33 %) switched to an alternative TKI. Reasons for switching included intolerance (79 %) and resistance (21 %). Among the 60 patients who switched due to intolerance, 53 (88 %) were able to achieve or maintain a major molecular response (MMR) with 5-year progression-free survival (PFS) 90.5 % (95 % CI 90.4–90.6 %). However, amongst the 16 patients who switched due to resistance, 8 patients (50 %) were able to achieve MMR with 5-year PFS 80.4 % (95 % CI 80.2–80.6 %). Most patients who switched due to intolerance remained on their second-line TKI. Patients who switch for intolerance continue to enjoy excellent long term clinical outcomes.